Preserved in Portico This version is not peer-reviewed
Mass Intake of Hydroxychloroquine or Chloroquine in the Present Context of the COVID-19 Outbreak: Possible Consequences in Endemic Malaria Settings
: Received: 12 April 2020 / Approved: 13 April 2020 / Online: 13 April 2020 (07:47:36 CEST)
A peer-reviewed article of this Preprint also exists.
Journal reference: Medical Hypotheses 2020, 143
World is currently experiencing a new pandemic for which no curative treatment is available. At this time, coronavirus disease 2019 (Covid-19) has reached 183 countries and has caused several deaths. Many reports presented chloroquine (CQ) and hydrochloroquine (HCQ), former drugs used against malaria, as the best current choice to fight this terrible disease. As these molecules had been withdrawn in malaria treatment policy due to chemoresistance, their reintroduction could have some consequences. Though local malaria prevalence could decrease for a while, molecular changes are likely to happen on some plasmodium falciparum genes involved in conferring drug resistance. This could threaten efforts in malaria control, if these molecules are widely administered.
malaria; COVID-19; SARS-COV-2; chloroquine; hydroxychloroquine
MEDICINE & PHARMACOLOGY, Pharmacology & Toxicology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.